National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Indicated in combination with paclitaxel for the treatment of adult patients with advanced GC or gastro oesophageal junction (GEJ) adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy and as monotherapy for the treatment of adult patients with advanced GC or GEJ adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate.

 

Rapid Review

Commenced Completed Outcome
20/12/2014 23/12/2014 Full Pharmacoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
03/12/2015  26/07/2016 Reimbursement Not Recommended at the Submitted Price.

Summary